Abbott filed suit against Perrigo on 31 October 2011 over patent infringement.
Androgel 1.0% (testosterone gel 1.0%) is used in the treatment of adult males who have low or no testosterone.
Perrigo chairman and CEO Joseph C Papa said the move implies the company’s investment in new products and expansion of their extended topicals pipeline.
"As always, Perrigo is committed to making quality healthcare more affordable for our customers," Papa added.